What it is
Thymosin Alpha-1, usually shortened to TA1, is a peptide — a short chain of amino acids, the building blocks of proteins — that your body already makes. It is 28 amino acids long and comes from a larger parent protein called prothymosin alpha. The man-made version is called thymalfasin and is sold as Zadaxin.
It is produced by the thymus, a small gland behind the breastbone where T-cells learn their job. T-cells are the immune system's main fighters: they attack infections, kill virus-infected cells and remove abnormal cells. TA1 is the signal the thymus uses to turn raw T-cells into trained ones.
The thymus shrinks after puberty. By your 40s and 50s much of it has been replaced by fat. That is why the immune system weakens with age: fewer new T-cells, weaker existing ones, poorer response to vaccines, more infections. TA1 aims to replace the signal the shrinking thymus no longer sends.
It is approved in over 35 countries for chronic hepatitis B, chronic hepatitis C and as an add-on to some cancer treatments. More than 11,000 people have taken it across more than 30 clinical trials, which makes it one of the most studied immune peptides.
Unlike most immune boosters, it balances rather than only stimulates. If the immune system is underperforming it brings it up; if it is overactive it helps calm it.
It arrives as a dry powder in a sealed vial. You add bacteriostatic water — sterile water with a preservative — then inject just under the skin, a subcutaneous injection.
Thymosin Alpha-1 (TA1) is a naturally occurring 28-amino-acid peptide, molecular weight 3,108 daltons, cleaved from the precursor prothymosin alpha and secreted by the thymus. The synthetic form is thymalfasin (Zadaxin).
Its endogenous role is T-cell maturation and immune regulation. Thymic involution begins after puberty; by the fifth and sixth decades much of the functional tissue is replaced by fat, thymic output falls and immunosenescence follows — fewer naive T-cells, reduced function, poor vaccine responsiveness and higher infection and cancer rates. Declining endogenous TA1 is the rationale for use in ageing adults.
TA1 is approved in over 35 countries for chronic hepatitis B, chronic hepatitis C and as an adjunct in certain cancers, with over 11,000 human subjects across more than 30 clinical trials. It holds FDA orphan drug status for certain conditions, was placed on the FDA Category 2 bulk substance list in 2023, removed in September 2024, and as of early 2026 is expected to move to Category 1. It is available as a research chemical.
The distinguishing pharmacology is bidirectional immunomodulation rather than pure stimulation: it raises underperforming cell-mediated immunity and increases anti-inflammatory signalling in overactive states. Documented activities span increased T-cell production (up to 30%), enhanced NK activity, replenished white cell counts, antiviral effects, vaccine enhancement, anti-inflammatory effects, healing and angiogenesis, and antioxidant support via glutathione peroxidase and dismutase.
Subcutaneous administration after reconstitution with bacteriostatic water.
How it works
TA1 works in several connected ways.
Sharpening the sensors. Immune cells carry sensors called Toll-like receptors that spot different threats — think of them as security cameras. TA1 switches on two of them, TLR-2 and TLR-9. That wakes up the body's first-line defences and boosts interferon, the body's main antiviral signal.
Training T-cells. It helps immature T-cells mature, increases the helper T-cells that coordinate the response and the killer T-cells that destroy infected cells, and restores T-cells worn out by long fights. Exhausted T-cells show markers such as PD-1 and Tim-3; TA1 reduces these, effectively switching the cells back on.
Waking natural killer cells. These patrol for virus-infected and early tumour cells. TA1 activates them, and in animal studies restored their activity toward normal in immunosuppressed subjects.
Helping the teachers. Dendritic cells show T-cells what to attack. TA1 helps them mature and produce IL-12, which drives the arm of immunity that kills infected cells.
Balancing signals. It raises IL-2 and interferon-gamma when immunity is low, raises the calming signal IL-10 when the system is overactive, and adjusts TNF-alpha depending on context. This is why it can both boost and calm.
Fighting viruses. It slows viral copying inside cells and makes infected cells display more of their contents (MHC class I) so killer T-cells can find them.
Cancer surveillance. It flips tumour-supporting M2 macrophages to tumour-attacking M1 macrophages and makes tumour cells more visible.
TA1 acts through several interlocking pathways.
TLR agonism. It directly activates TLR-2 and TLR-9, engaging NF-kB (the master switch for inflammatory and immune gene transcription) and IRF3 (interferon induction). Romani et al. (2004) confirmed the TLR-2/TLR-9 agonist activity and dendritic cell activation via p38 MAPK/NF-kB.
T-cell enhancement. Promotes thymic maturation of immature T-cells, increases CD4+ helper and CD8+ cytotoxic subsets, and restores function in age-, infection- or treatment-related decline. In severe lymphocytopenia it enhances thymic output and reverses exhaustion, reducing PD-1 and Tim-3 expression on CD8+ cells; Mishra et al. (2026) additionally reported reduced LAG-3 and increased granzyme B secretion.
NK activation. Direct activation; in immunosuppressed animal models NK activity was restored toward normal.
Dendritic cell maturation. Via p38 MAPK and NF-kB, with increased IL-12 output driving Th1 polarisation and bridging innate detection to adaptive response.
Cytokine modulation. Increases IL-2 (T-cell growth factor), interferon-gamma (macrophage activation, antiviral defence) and IL-10 (anti-inflammatory), and modulates TNF-alpha contextually. This context-dependent pattern underlies the bidirectional immunomodulation.
Antiviral. Direct inhibition of viral replication and viral protein expression in infected cells, plus upregulated MHC class I presentation making infected cells visible to CD8+ cytotoxic T-cells.
Tumour microenvironment. Repolarises tumour-associated macrophages from M2 to M1 and increases MHC class I on tumour cells.
Pharmacokinetics. Subcutaneous absorption is rapid, peak serum within about 2 hours, serum half-life approximately 2 hours, baseline within 24 hours, no accumulation with repeated dosing. Renal excretion accounts for 30 to 60% of the dose; the remainder is cleared by peptidase degradation.
What it does
Immune cells: it increases T-cell production — by up to 30% — raises helper and killer T-cell numbers, boosts natural killer cells, and replenishes white blood cell count.
Infections: it helps combat viral infections and may reduce viral load in hepatitis and HIV. It has been most studied in chronic hepatitis B and C, where trials showed improved viral clearance, especially alongside interferon. In Mutchnick et al. (1991), 6 of 7 treated hepatitis B patients (86%) cleared the virus from blood against 1 of 5 on placebo.
Vaccines: it improves how well vaccines work, especially in older adults. In Gravenstein et al. (1989), 90 elderly men had stronger antibody responses to flu vaccine, and a Phase 2 study cut flu cases from 19% to 6%.
Inflammation: it raises IL-10 and adjusts TNF-alpha, so it can calm overactive immunity. Some users with autoimmune conditions report benefit, but this needs medical supervision.
Cancer: it is used alongside — never instead of — standard treatment in liver cancer, melanoma and non-small cell lung cancer, restoring immunity during chemotherapy and helping the body recognise tumour cells.
Severe illness: in a retrospective COVID-19 review (Liu et al., 2020) mortality fell from 30.00% to 11.11%, but the large TESTS sepsis trial (2025) found no mortality reduction.
Repair: it is also associated with healing, tissue repair, new blood vessel growth and support for the antioxidant enzymes glutathione peroxidase and dismutase.
Cell-mediated immunity: increased T-cell production (up to 30%), expanded CD4+ and CD8+ subsets, reversed exhaustion, enhanced NK activity, replenished white blood cell count.
Chronic viral infection: improved viral clearance in hepatitis B and C, particularly with interferon, with sustained responses on long-term follow-up and better tolerability than interferon alone. Mutchnick et al. (1991): 6 of 7 treated patients (86%) cleared HBV-DNA versus 1 of 5 placebo, with gains in lymphocyte, CD3 and CD4 counts and interferon-gamma, persisting through 26 months. Sugahara et al. (2002): over 24 weeks, increased intrahepatic NKT and CD8+ CTLs; 2 of 7 (28.6%) normalised liver enzymes with undetectable HBV-DNA. May reduce viral load in HIV.
Vaccine response: Gravenstein et al. (1989), 90 elderly men (65 to 99), augmented influenza antibody response with no toxicity; Phase 2 influenza incidence 19% versus 6%.
Oncology adjunct: Costantini et al. (2019) — improved overall and recurrence-free survival after HCC surgery, longer median survival with sorafenib, 36 to 50% objective response in melanoma Phase II combinations, median OS 38.4 months versus 8 months when given before ipilimumab, and an NSCLC meta-analysis (10 RCTs, 724 patients) showing higher response and tumour control rates and increased CD4+ and NK cells. Mishra et al. (2026): enhanced CD8+ cytotoxicity against breast cancer cells in vitro. May improve chemotherapy outcomes.
Critical illness: Liu et al. (2020), 76 severe COVID-19 cases, mortality 30.00% versus 11.11% (retrospective; other studies mixed). TESTS (BMJ, 2025), 1,089 adults, 22 centres: 28-day mortality 23.4% versus 24.1%, no benefit. Gu et al. (2025) meta-analysis of 11 RCTs (1,927 patients): OR 0.73 (95% CI 0.59 to 0.90), benefit lost in high-quality multicentre trials.
Anti-inflammatory: IL-10 induction and TNF-alpha modulation.
Also reported: healing and tissue repair, angiogenesis, antioxidant support via glutathione peroxidase and dismutase.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Increases T-cell production — by up to 30% — and restores worn-out T-cells.Limited human data
- Boosts the activity of natural killer cells, which destroy infected and abnormal cells.Limited human data
- Replenishes white blood cell count.Limited human data
- Helps combat viral infections and may reduce viral load in hepatitis and HIV.Human trials
- Improved viral clearance in chronic hepatitis B and C, especially alongside interferon.Human trials
- Enhances how well vaccines work — flu cases fell from 19% to 6% in a Phase 2 study.Human trials
- Anti-inflammatory effects through IL-10 and TNF-alpha balancing; may help calm overactive immunity.Animal or lab only
- Supports cancer treatment protocols and may improve chemotherapy outcomes.Human trials
- Promotes healing and tissue repair.Animal or lab only
- Stimulates angiogenesis — the formation of new blood vessels.Animal or lab only
- Antioxidant support through glutathione peroxidase and dismutase.Animal or lab only
- Enhances cell-mediated immunity, the arm that attacks infected cells directly.Limited human data
- Users report fewer and shorter illnesses and, sometimes, better energy.Anecdotal
- Likely to benefit: people with weakened immunity, some autoimmune disorders (with supervision), ageing adults, and anyone wanting a better vaccine response.Anecdotal
- Increased T-cell production (up to 30%), expanded CD4+ and CD8+ subsets, reversal of exhaustion markers PD-1, Tim-3 and LAG-3.Limited human data
- Enhanced natural killer cell activity.Limited human data
- Replenished white blood cell count.Limited human data
- Antiviral activity; may reduce viral load in hepatitis and HIV.Human trials
- Improved viral clearance in chronic hepatitis B and C with sustained long-term responses; better tolerated than interferon alone.Human trials
- Enhanced vaccine effectiveness — 19% to 6% influenza incidence in Phase 2 (Gravenstein et al., 1989).Human trials
- Anti-inflammatory effects via IL-10 induction and contextual TNF-alpha modulation.Animal or lab only
- Oncology adjunct: improved survival and response rates in HCC, melanoma and NSCLC (Costantini et al., 2019); may improve chemotherapy outcomes.Human trials
- Promotes healing and tissue repair.Animal or lab only
- Stimulates angiogenesis.Animal or lab only
- Antioxidant support via glutathione peroxidase and dismutase.Animal or lab only
- Enhanced cell-mediated immunity through TLR-2/TLR-9, dendritic cell and Th1 pathways.Limited human data
- Mitigation of immunosenescence and restored T-cell diversity in the elderly (Simonova et al., 2025).Limited human data
- Target populations: immunocompromise, autoimmune disorders under supervision, ageing adults with thymic involution, and vaccine responsiveness.Anecdotal
What to expect
Do not expect to feel anything the next day. TA1 works at the level of immune cells, and those changes build over weeks. There is no obvious sensation the way there is with growth hormone peptides or stimulants.
The drug itself is in and out quickly: it peaks about 2 hours after injection and is back to baseline within 24 hours. It does not build up in the body. The effect on the immune system, however, lasts far longer than the drug does.
The trials that showed benefit ran for months — typically 6 to 12 months for hepatitis. For general immune support, most practitioners recommend 4 to 8 week cycles.
Users most often report fewer colds and flu, or recovering in days instead of weeks. Some report better energy, probably because a healthier immune system is less draining. People with lingering post-viral conditions sometimes report meaningful improvement. Those with autoimmune conditions report mixed results; some describe an initial flare before settling, so medical supervision matters.
One HIV-positive user reported white blood cells rising from 3.6 to 4.4 thousand/uL, lymphocytes from 2,096 to 2,618/uL and CD4 cells from 476 to 551/uL after six injections of 1.67 mg — and all of it reversing within two weeks of stopping.
That is the key point: benefits are temporary. TA1 fills in for a thymus that no longer does the job, so when you stop, the decline resumes. Side effects are usually mild: injection site redness, brief tiredness after the first few doses, occasionally a mild headache or poor sleep.
Pharmacokinetics (Ancell et al., 2001): rapid subcutaneous absorption, peak serum concentration within about 2 hours, serum half-life approximately 2 hours, return to baseline within 24 hours, no accumulation with repeated dosing. Renal excretion 30 to 60%, remainder via peptidase degradation. The pharmacodynamic effect — cellular immunomodulation — is decoupled from plasma exposure and develops over weeks.
No acute subjective signal should be expected. Efficacy in trials emerged over months, typically 6 to 12 months in chronic hepatitis. General immune support protocols are usually run as 4 to 8 week cycles.
In practice the most consistent report is reduced infection frequency and duration. Improved energy is reported, plausibly secondary to reduced immune burden rather than a direct stimulant effect. Post-viral syndromes and long COVID are reported to improve to varying degrees. Autoimmune reports are mixed: reduced flare frequency in Hashimoto's thyroiditis for some, no change or transient worsening before improvement for others — consistent with recalibration under bidirectional modulation, and a reason for close supervision.
The most concrete anecdotal data comes from tracked bloodwork. One HIV-positive user reported WBC 3.6 to 4.4 thousand/uL, lymphocytes 2,096 to 2,618/uL and CD4 476 to 551/uL after six injections of 1.67 mg, reversing within two weeks of cessation.
Benefits are compensatory rather than curative: TA1 substitutes for declining thymic signalling and effects fade after discontinuation, unlike a completed tissue-healing cycle. Cycling is therefore practical rather than pharmacologically required.
Tolerability across over 11,000 subjects is favourable (Dinetz and Lee, 2024), with no serious adverse events attributable to TA1 alone in trials. Users report injection site irritation and transient fatigue after early doses as most common; mild headache, insomnia and mild nausea are uncommon; erythema, transient injection-site muscle discomfort and joint pain are rare. Most resolve within the first week.
Reconstitution and dosing
One vial size: 10 mg. Mix with 2 mL of bacteriostatic water. Add the water slowly down the side of the vial rather than onto the powder, then swirl gently. Do not shake.
Mixed that way, every 5 units on an insulin syringe (0.05 mL) hold 250 micrograms (mcg). The standard 1.6 mg dose is 32 units (0.32 mL).
Standard protocol: 1.6 mg twice a week, commonly Monday and Thursday. This is the dose used in almost all clinical trials and matches the approved Zadaxin dose. No fasting is needed and any time of day is fine — just be consistent.
How long to run it depends on the goal. For general immune support, run 4 to 8 weeks, then take 4 weeks off, or run it seasonally through cold and flu months. For chronic infection support, trials ran 6 to 12 months; this needs a doctor's supervision and is often combined with other treatments. For vaccine enhancement, start 2 weeks before the jab and continue 2 to 4 weeks after.
An intensive protocol has also been described for severe or acute infection — the same 1.6 mg dose every day for two weeks — along with a wider cycle range of 4 to 24 weeks on with 2 to 12 weeks off. The 4 to 8 week cycle is the better-supported general guidance.
Inject under the skin in the abdomen, thigh or upper arm; all work equally well because TA1 acts throughout the body. Rotate sites to avoid irritation. There is no ramp-up: you start at the full dose.
Single presentation: 10 mg reconstituted with 2 mL bacteriostatic water, giving 250 mcg per 5 insulin units (0.05 mL). The 1.6 mg dose is 32 units (0.32 mL); the arithmetic reconciles exactly.
Standard protocol: 1.6 mg (1,600 mcg) subcutaneously twice weekly, commonly Monday and Thursday. This is the dose used in the overwhelming majority of trials and the registered thymalfasin (Zadaxin) dose, originally derived as 900 mcg per square metre of body surface area. No fasting requirement and no time-of-day restriction — TA1 does not interact with food absorption as GH secretagogues do. Weekly exposure 3.2 mg.
Duration by application: general immune support, 4 to 8 weeks with 4 weeks off between cycles or seasonal use; chronic infection support, 6 to 12 months based on trial durations, often combined with other therapies, duration guided by clinical response, physician supervision required; vaccine enhancement, start 2 weeks before vaccination and continue 2 to 4 weeks after.
There is no pharmacological requirement to cycle — trials ran continuously for 6 to 12 months without issues. Cycling in general use is driven by cost and by the observation that immune enhancement persists for some time after stopping before fading.
An intensive variant of 1.6 mg daily for two weeks in severe or acute infection (weekly exposure 11.2 mg) has also been described, along with a 4–24 week on, 2–12 week off cycle range; the application-specific durations above supersede that range.
Administration is systemic; abdomen, thigh or upper arm are equivalent. Rotate sites. No titration — both trial and practical protocols begin at full dose.
Standard, 10 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
5 mg/mL · 50 mcg per unit
Cycle: 4 to 8 weeks for general immune support, then 4 weeks off or run seasonally; 6 to 12 months for chronic infection support under physician supervision; for vaccine enhancement start 2 weeks before and continue 2 to 4 weeks after vaccination · Frequency: Twice weekly (commonly Monday and Thursday); subcutaneous in abdomen, thigh or upper arm; no fasting, no time-of-day restriction
| When | Dose | Draw | How often |
|---|---|---|---|
| Whole cycle — 32 units (0.32 mL) | 1.6 mg | 32 units | 2 days per week |
Alternative protocols
Alternative protocols reflect older community practice and are kept for reference.
Alternative, 10 mg vial — standard protocol
Mix with 2 mL (200 units) of bacteriostatic water.
5 mg/mL · 50 mcg per unit
Cycle: 4–24 week cycle, then a 2–12 week washout · Frequency: Twice weekly, spaced 3–4 days apart; subcutaneous; night dosing recommended, morning acceptable; with or without food
| When | Dose | Draw | How often |
|---|---|---|---|
| Whole cycle — 32 units | 1.6 mg | 32 units | 2 days per week, 3–4 days apart |
Alternative, 10 mg vial — intensive protocol (severe or acute infection)
Mix with 2 mL (200 units) of bacteriostatic water.
5 mg/mL · 50 mcg per unit
Cycle: Two weeks · Frequency: Daily; subcutaneous; night dosing recommended, morning acceptable; with or without food
| When | Dose | Draw | How often |
|---|---|---|---|
| Two weeks — 32 units | 1.6 mg | 32 units | 1×/day |
10 mg in 2 mL is 5 mg/mL, or 50 mcg per unit. Draw 32 units (0.32 mL) for 1600 mcg.
Who should avoid it
- Do not use if you have had an organ transplant and take drugs to stop your body rejecting it (such as tacrolimus, cyclosporine, or mycophenolate). TA1 pushes the immune system up, which works directly against those drugs and could put the transplant at risk.
- Do not use if you have had an allergic reaction to Thymosin Alpha-1 or anything in the vial.
- Do not use if you are on cancer immunotherapy such as checkpoint inhibitors (Keytruda, Opdivo, sintilimab) unless your oncologist has clearly said yes. A 2026 case report described high fever, rash, fluid in the lungs, and multiple organ failure when TA1 was combined with the PD-1 inhibitor sintilimab. Two immune-boosting treatments together can push the immune system too far.
- Be careful if you have an autoimmune condition. TA1 is said to balance the immune system rather than only boost it, and some people with Hashimoto's report fewer flares, but others report no change or a worsening before things settle. If you take a biologic such as a TNF inhibitor (Humira, Hyrimoz, Enbrel, Remicade), TA1 can switch back on the immune activity that drug is meant to hold down. Your prescribing doctor must know and agree before you start.
- Be careful in pregnancy or while breastfeeding — safety has not been established.
- Be careful with children — safety has not been established.
- Be careful during active cancer treatment. TA1 may help as an add-on, but only under an oncologist's supervision, never on your own.
- Users report that TA1 has been safely combined with interferon, ribavirin, chemotherapy drugs, and various vaccines in clinical trials, so those are not the concern; the immune-suppressing and immune-activating drugs above are.
- Absolute contraindication: solid-organ transplant recipients on maintenance immunosuppression (tacrolimus, cyclosporine, mycophenolate). TA1 upregulates T-cell and NK-cell function and directly opposes the pharmacological immunosuppression maintaining graft viability.
- Absolute contraindication: known hypersensitivity to Thymosin Alpha-1 or any excipient.
- Absolute contraindication without explicit oncologist approval: concurrent checkpoint inhibitors or other cancer immunotherapy (PD-1/PD-L1 inhibitors such as Keytruda, Opdivo, sintilimab). Li et al. (2026) documented a multisystemic immune-related adverse event — high fever, rash, interstitial pulmonary oedema, multiple organ failure — in a nasopharyngeal carcinoma patient receiving TA1 with sintilimab. The mechanism is additive immune activation, not TA1 toxicity in isolation, but the outcome is the same. This is distinct from the published melanoma data where TA1 preceded ipilimumab under trial conditions.
- Caution: autoimmune disease. TA1 is described as a bidirectional modulator (IL-10 induction, TNF-alpha modulation) rather than a blunt stimulant, which is the mechanistic argument for its use in autoimmunity, and users with Hashimoto's thyroiditis report reduced flare frequency. Reports in more aggressive autoimmune disease are mixed, including initial worsening before improvement. Concurrent TNF inhibitors (Humira, Hyrimoz, Enbrel, Remicade) are a direct pharmacodynamic conflict: TA1 can upregulate immune function the biologic is intentionally suppressing. Prescriber sign-off is required.
- Caution: pregnancy and lactation — safety not established.
- Caution: paediatric use — safety not established.
- Caution: active cancer treatment. Adjunctive use is supported in hepatocellular carcinoma, melanoma, and NSCLC data, but only alongside conventional therapy under oncologist supervision. Earlier guidance on this page noted angiogenic activity, but the oncology concern here is immunotherapy interaction, not tumour vascularisation.
- Documented safe co-administration in clinical trials: interferon, ribavirin, chemotherapy agents, and various vaccines.
Side effects
- In trials covering over 11,000 people, TA1 was well tolerated. No serious side effects caused by TA1 on its own have been reported in clinical trials. It is much gentler than interferon, which often causes flu-like symptoms, depression, and heavy fatigue.
- Common (users report): redness or mild swelling where you inject, and tiredness after the first few doses that passes.
- Uncommon (users report): mild headache, usually only after the first injection; trouble sleeping; mild nausea.
- Rare (users report): skin redness, brief muscle discomfort at the injection site, joint pain.
- Also reported: fever, muscle aches, and vomiting. These are described as rare and generally mild.
- Most side effects are mild and settle within the first week.
- The one serious published reaction — high fever, rash, fluid in the lungs, and organ failure — happened when TA1 was combined with a cancer immunotherapy drug, not from TA1 alone.
- Rotate injection sites between the abdomen, thigh, and upper arm to limit irritation.
- Dinetz and Lee (2024), reviewing over 11,000 human subjects across more than 30 clinical trials, concluded TA1 is well tolerated across all studied applications. No serious adverse events attributable to TA1 alone have been reported in clinical trials. The tolerability profile contrasts sharply with interferon (flu-like syndrome, depression, severe fatigue).
- Common (user reports): injection site irritation — erythema, mild swelling; transient fatigue after the first few doses.
- Uncommon (user reports): mild headache, typically first injection only; insomnia; mild nausea.
- Rare (user reports): erythema, transient myalgia at the injection site, arthralgia.
- Also reported: fever, myalgia, vomiting — described as rare and generally mild. The fever–myalgia–fatigue cluster is consistent with cytokine-mediated immune activation rather than off-target toxicity, but still needs distinguishing from intercurrent infection.
- Most reported effects are mild and resolve within the first week of use.
- The single published severe adverse event (Li et al., 2026) — fever, rash, interstitial pulmonary oedema, multiple organ failure — occurred with concurrent sintilimab and was attributed to excessive immune activation from combined immunostimulatory therapy.
- Systemic modulator; no site-specific injection required. Rotate between abdomen, thigh, and upper arm.
What the evidence shows
TA1 is one of the most studied immune peptides there is. It is approved in over 35 countries as thymalfasin (brand name Zadaxin) for chronic hepatitis B and C and as an add-on in some cancers, and more than 11,000 people have taken part in over 30 clinical trials.
Hepatitis B. Mutchnick et al. (1991) ran a small placebo-controlled trial in 12 patients. Six of seven treated patients (86%) cleared hepatitis B virus DNA from their blood, against one of five on placebo, with no side effects and results lasting through 26 months of follow-up. Sugahara et al. (2002) treated seven patients for 24 weeks; two of seven (28.6%) reached normal liver enzymes and undetectable virus.
Vaccines. Gravenstein et al. (1989) gave TA1 with the flu vaccine to 90 men aged 65 to 99 in a double-blind placebo-controlled study and saw a stronger antibody response with no toxicity. A Phase 2 study found flu cases fell from 19% with vaccine alone to 6% with vaccine plus TA1.
COVID-19. Liu et al. (2020) looked back at 76 severe cases in Wuhan and found deaths fell from 30.00% untreated to 11.11% treated. This was not a randomised trial, and other COVID studies gave mixed results.
Sepsis. The biggest trial ever run, TESTS (Wu, Pei et al., 2025, BMJ), covered 1,089 adults at 22 centres and found no difference in 28-day deaths: 23.4% with TA1 versus 24.1% with placebo. A 2025 meta-analysis (Gu et al.) of 11 trials and 1,927 patients did find a benefit (OR 0.73), but it vanished when only high-quality trials were counted. The fair reading is that TA1 does not broadly cut sepsis deaths, though some groups with weakened immunity might benefit.
Cancer. Costantini et al. (2019) reviewed the add-on data: better survival after liver cancer surgery, 36 to 50% response rates in melanoma combinations, and a lung cancer meta-analysis of 10 trials and 724 patients showing better response rates. In one melanoma dataset, TA1 before ipilimumab gave 38.4 months median survival versus 8 months without.
Safety. Dinetz and Lee (2024) reviewed all the trial data and called TA1 well tolerated and effective.
Thymalfasin (Zadaxin) is approved in over 35 countries for chronic hepatitis B, chronic hepatitis C, and as an oncology adjunct, with over 11,000 human subjects across more than 30 clinical trials.
Mechanism. Romani et al. (2004, Blood) confirmed TLR-2 and TLR-9 agonism, dendritic cell activation via p38 MAPK/NF-kB, and induction of antifungal Th1 resistance — the molecular bridge between innate and adaptive immunity.
Hepatitis B. Mutchnick et al. (1991): placebo-controlled pilot, 12 patients, twice-weekly dosing for 6 months; 6 of 7 treated (86%) cleared serum HBV-DNA versus 1 of 5 placebo, with biopsy confirmation, improved lymphocyte, CD3 and CD4 counts and IFN-gamma production, no adverse effects, and persistence through 26 months. Sugahara et al. (2002): 7 patients, 24 weeks, increased intrahepatic NKT cells and CD8+ CTLs; 2 of 7 (28.6%) achieved normalised enzymes and undetectable HBV-DNA.
COVID-19. Liu et al. (2020): retrospective, 76 severe cases, two Wuhan hospitals; mortality 30.00% untreated versus 11.11% treated, via restoration of T-cell counts in severe lymphocytopenia and reduced PD-1 and Tim-3 on CD8+ T cells. Retrospective design; other COVID studies were mixed.
Sepsis. TESTS (Wu, Pei et al., 2025, BMJ): multicentre, double-blind, placebo-controlled Phase 3, 22 Chinese centres, 1,089 adults; no reduction in 28-day all-cause mortality (23.4% versus 24.1%, HR 0.99). Gu et al. (2025) meta-analysis of 11 RCTs (1,927 patients): OR 0.73 (95% CI 0.59 to 0.90), but the effect disappeared when restricted to high-quality multicentre trials; low-to-moderate credibility signals in cancer, diabetes, and coronary heart disease subgroups.
Oncology adjunct. Costantini et al. (2019, Frontiers in Oncology): adjuvant TA1 after HCC resection improved overall and recurrence-free survival; added to sorafenib it increased median survival; melanoma Phase II combinations yielded 36 to 50% objective response rates; TA1 before ipilimumab gave median OS 38.4 months versus 8 months; NSCLC meta-analysis of 10 RCTs (724 patients) showed increased overall response rate, tumour control rate, CD4+ and NK cells. Mishra et al. (2026, Human Immunology): enhanced CD8+ cytotoxicity against breast cancer cells, increased granzyme B, reduced PD-1, TIM-3 and LAG-3.
Vaccine. Gravenstein et al. (1989): double-blind placebo-controlled, 90 men aged 65 to 99, augmented influenza antibody response, no toxicity; Phase 2 incidence 19% versus 6%.
Safety and ageing. Dinetz and Lee (2024): well tolerated and effective across 11,000+ subjects. Simonova et al. (2025): improves vaccine response in the elderly, mitigates immunosenescence, restores T-cell diversity; long-term elderly safety data still needed.
Pharmacokinetics. Peak serum concentration within about 2 hours subcutaneously, serum half-life approximately 2 hours, baseline within 24 hours, no accumulation; 30 to 60% renal excretion, remainder peptidase degradation.
User reports
From public forums
These are anecdotal accounts, not research findings, and should be weighed accordingly.
The most common thing users report is fewer infections. People who used to catch every cold and flu describe getting through winter without getting sick, or recovering in days rather than weeks. This is the most consistent report by far.
Some users report better energy. That is more likely a knock-on effect of a healthier immune system than a direct stimulant effect. TA1 is not something you feel the next day; changes happen slowly at the cellular level over weeks.
People with long-running viral problems, post-viral fatigue such as long COVID, and chronic fatigue report varying degrees of improvement. One user described TA1 as having rescued them from crippling fatigue after COVID.
Autoimmune users report mixed results. Some with Hashimoto's thyroiditis report fewer flares. Others with more aggressive conditions report no change, or a worsening before things improve — which fits the idea that the immune system may recalibrate in a way that feels like a flare before settling. This use needs a doctor closely involved.
The firmest anecdotal data comes from people tracking bloodwork. One HIV-positive user reported white blood cells rising from 3.6 to 4.4 thousand/uL, lymphocytes from 2,096 to 2,618/uL, and CD4 cells from 476 to 551/uL after just six injections of 1.67mg each. The gains reversed within two weeks of stopping.
That last point is the pattern users describe most consistently: benefits fade when you stop. Unlike a healing peptide where repaired tissue stays repaired, TA1 is standing in for a thymus that is no longer doing its job. Most users therefore run cycles — typically 4 to 8 weeks on then 4 weeks off — or use it seasonally through cold and flu months.
Side effects reported are usually minimal: mild injection site irritation most often, sometimes tiredness after the first few doses, a mild headache after the first injection, or trouble sleeping.
Anecdotal data aggregated from forums and clinic reports; not equivalent to published evidence.
Infection frequency. The dominant report is reduced frequency and duration of respiratory infections across a protocol — users who previously caught every circulating virus describe uneventful winters or recovery in days rather than weeks.
Energy. Some users report improved energy, plausibly secondary to reduced immune burden rather than any direct stimulant action. Subjective onset is slow; TA1 does not produce next-day sensation, and users compare it unfavourably to GH secretagogues in that respect.
Chronic and post-viral states. Users with chronic viral infection, long COVID, and chronic fatigue report variable improvement, including one account of resolution of debilitating post-COVID fatigue and others of lingering viral conditions clearing.
Autoimmunity. Mixed. Hashimoto's thyroiditis users report reduced flare frequency; users with more aggressive autoimmune disease report no change or initial worsening before improvement, consistent with bidirectional modulation producing a transient recalibration that presents like a flare. Close medical supervision is emphasised.
Bloodwork. One HIV-positive user documented WBC 3.6 to 4.4 thousand/uL, lymphocytes 2,096 to 2,618/uL, and CD4 476 to 551/uL after six subcutaneous injections of 1.67mg, with reversal within two weeks of cessation.
Transience. The most consistent finding: benefits fade after discontinuation, in contrast to BPC-157 where healed tissue remains healed. This matches the pharmacology — TA1 substitutes for declining thymic output, and the decline resumes without it. Users therefore cycle 4 to 8 weeks on, 4 weeks off, or run seasonally.
Tolerability. Most users report minimal to no side effects. Injection site irritation is most common; transient fatigue after initial doses, first-injection headache, and insomnia are occasional.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
No interaction concerns. These growth hormone peptides add muscle repair and anti-ageing support alongside the immune work. They need to be taken fasted; TA1 does not, so keep the two on their own schedules.
No interaction. GHRH analogue plus GHS-R1a agonist for regenerative and anti-ageing support. Different timing requirements: GH secretagogues require fasting, TA1 is food-independent — run separate schedules.
No interaction concerns. Like the other growth hormone peptides it needs fasting, so dose it separately from TA1.
No interaction. GHRH analogue; fasting-dependent timing separate from TA1's schedule.
No interaction concerns — TA1 works on the immune system, BPC-157 on tissue healing, so they can run together with no timing conflicts. If you have an autoimmune condition and are on a biologic such as a TNF inhibitor, get BPC-157 cleared by your doctor; that is an autoimmune management issue, not a TA1 interaction.
No interaction; entirely different mechanisms (immune modulation versus tissue repair). No timing conflicts. In autoimmune patients on biologics such as TNF inhibitors, BPC-157 requires prescriber clearance independently of TA1 — an autoimmune management issue, not a TA1 interaction.
No interaction concerns, same as BPC-157: healing rather than immune work. Despite the shared name it is a completely different peptide from TA1. Same doctor-clearance note applies if you are on a biologic.
No interaction. Thymosin beta 4 — 43 amino acids, actin upregulation — is structurally and functionally distinct from TA1 despite the shared name. Same prescriber-clearance caveat in autoimmune patients on biologics.
KLOW contains BPC-157, TB-500, GHK-Cu, KPV, and VIP. The KPV part calms inflammation through a different route from TA1, so together they cover both immune weakness and chronic inflammation.
Contains BPC-157, TB-500, GHK-Cu, KPV, and VIP. KPV acts via the melanocortin pathway for anti-inflammatory effect, complementing TA1's immune modulation through independent pathways. Suited to combined immune dysfunction and chronic inflammation.
Works on inflammation through a different route from TA1. In practice, users are advised to get inflammation under control with TA1 and KPV before adding metabolic peptides.
Melanocortin-pathway anti-inflammatory complementing TA1. In practice, controlling inflammation with TA1 and KPV precedes adding metabolic compounds such as MOTS-c.
- GLP-1 agonists (retatrutide, semaglutide, tirzepatide)
No interaction concerns. Completely different mechanisms; they can be run at the same time.
No interaction. Incretin receptor agonism and immune modulation are mechanistically unrelated; concurrent use is unproblematic.
No interaction concerns. SS-31 works on the energy-producing parts of cells, not the immune system.
No interaction. Mitochondrial membrane-targeted; no overlap with immune modulation pathways.
No interaction concerns, but if you have a lot of inflammation, settle it first with TA1 and KPV before adding MOTS-c. Pushing metabolism on an inflamed body adds stress.
No interaction; AMPK signalling does not intersect immune modulation. Sequence matters: bring significant inflammation under control with TA1 and KPV before adding metabolic demand — pushing metabolic load on an inflamed system compounds stress.
Recommended as working with TA1 to restore immune function and extend healthy ageing.
Considered synergistic for immune restoration and healthy-ageing extension.
Recommended for supporting cell energy and immune cell function during longer TA1 use.
Suggested for mitochondrial support and immune cell function during extended TA1 exposure.
Recommended to reinforce antioxidant defences and reduce whole-body oxidative stress.
Suggested to reinforce antioxidant pathways and reduce systemic oxidative stress, a natural pairing given TA1's reported antioxidant properties.
Recommended for skin regeneration and healing alongside TA1. It is also one of the components of KLOW.
Suggested for skin regeneration and immune-modulated healing; also a KLOW component.
Common questions
How is Thymosin Alpha-1 different from taking vitamin C or zinc for immunity?
Vitamin C and zinc are raw materials that immune cells use. TA1 is a signal that directly activates and trains immune cells. Think of it as the difference between giving workers better tools and hiring a foreman who trains and directs them. Both help, but at completely different levels.
Vitamin C and zinc are cofactors supporting immune cell function. TA1 is a signalling peptide that activates and matures immune cells through defined receptor pathways — TLR-2 and TLR-9 agonism, dendritic cell maturation via p38 MAPK/NF-kB, and T-cell differentiation. Substrate provision versus upstream orchestration.
Can Thymosin Alpha-1 be used with an autoimmune condition?
Possibly, with care. TA1 balances the immune system in both directions, so in theory it can calm an overactive response, and some people with Hashimoto's report fewer flares. But if you take a biologic such as a TNF inhibitor (Humira, Hyrimoz, Enbrel), TA1 can switch back on what the drug is suppressing. Tell your prescribing doctor and get their sign-off first. Never run it behind your doctor's back if you are on immune-suppressing medication.
Nuanced. Bidirectional modulation — IL-10 induction and TNF-alpha modulation — is the mechanistic basis for potential benefit, and Hashimoto's users report reduced flare frequency. Concurrent TNF inhibitors are a direct pharmacodynamic conflict: TA1 upregulates immune function the biologic intentionally suppresses. Prescriber awareness and approval are mandatory before starting.
Will anything be felt after injecting?
Probably not in any obvious way. This is not like a growth hormone peptide where sleep or recovery improves noticeably. The effects are at the cellular level and show up as fewer infections, faster recovery when you do get ill, and possibly better blood results over time. Some people report more energy, but that is likely a knock-on effect.
Unlikely. Effects are immunological and cellular, accruing over weeks; there is no acute subjective signal comparable to GH secretagogues. Outcomes manifest as reduced infection frequency, shorter illness duration, and potentially improved lymphocyte and CD4 markers. Reported energy improvement is probably secondary to reduced immune burden.
Does Thymosin Alpha-1 need to be cycled?
There is no medical reason that forces cycling — trials ran continuously for 6 to 12 months without problems. For general immune support, though, most people run 4 to 8 weeks on with breaks in between, partly for cost and partly because the benefit lingers for a while after stopping before gradually fading.
No pharmacological requirement; clinical trials ran 6 to 12 months continuously. For general immune support, in practice 4 to 8 week cycles with 4 weeks off, or seasonal use, are typical — partly cost-driven, partly because immune enhancement persists for a period after cessation before fading.
Does it need to be taken fasted or at a set time?
No. There is no fasting requirement and no time-of-day rule. TA1 does not interact with food the way growth hormone peptides do. Just keep a consistent schedule, such as Monday and Thursday.
No fasting requirement and no circadian constraint. Unlike GH secretagogues, TA1 has no food-absorption interaction. Consistency of schedule (commonly Monday and Thursday) is the only practical consideration.
Is Thymosin Alpha-1 the same as TB-500?
No. Despite the shared 'thymosin' name they are completely different peptides. TA1 is a 28 amino acid immune peptide. TB-500 (thymosin beta 4) is a 43 amino acid healing peptide. The name overlap is only because both were first isolated from thymus extracts.
No. TA1 is a 28-amino-acid immune modulator; TB-500 (thymosin beta 4) is a 43-amino-acid tissue repair peptide acting via actin upregulation. Distinct structures and functions; the shared name reflects common isolation from thymus tissue extracts.
Do the benefits last after stopping?
Users consistently report that they fade. TA1 is doing the job a shrinking thymus can no longer do, so when the signal stops, the decline resumes. One user's blood improvements reversed within two weeks of stopping. This is why most people cycle it or use it seasonally.
Consistently reported as transient. TA1 compensates for ongoing thymic involution rather than producing a durable structural change; discontinuation allows the decline to resume. One documented case showed WBC, lymphocyte, and CD4 gains reversing within two weeks of stopping — hence cyclical or seasonal use.
References
- King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitamins and Hormones. 2016;102:151-178.
- Dominari A, et al. Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology. 2020;9(5):67-78.
- Tao N, et al. Thymosin Alpha 1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules. 2023;28(8):3539.
- Sugahara S, et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatology Research. 2002;24(4):346-354.
- Garaci E, et al. Thymosin alpha 1 and cancer: action on immune effector and tumor target cells. Annals of the New York Academy of Sciences. 2012;1269:26-33.
- Romani L, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232-4239.
- Mutchnick MG, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-415.
- Gravenstein S, et al. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. Journal of the American Geriatrics Society. 1989;37(1):1-8.
- Liu Y, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clinical Infectious Diseases. 2020;71(16):2150-2157.
- Wu J, Pei F, et al. The efficacy and safety of thymosin alpha 1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583.
- Gu B, et al. Efficacy of thymosin alpha 1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology. 2025;15:1673959.
- Costantini C, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Frontiers in Oncology. 2019;9:873.
- Dinetz E, Lee E. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Alternative Therapies in Health and Medicine. 2024;30(1):6-12.
- Simonova MA, et al. Aging and Thymosin Alpha-1. International Journal of Molecular Sciences. 2025;26(23):11470.
- Mishra S, et al. A multipronged Ta1 reset of CD8+ T cell cytotoxicity against breast cancer. Human Immunology. 2026;87(3):111678.
- Li T, et al. A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1. Clinical Case Reports. 2026;14(2).
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. American Journal of Health-System Pharmacy. 2001;58(10):879-885.
This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.